187 related articles for article (PubMed ID: 1659052)
1. Oka/Merck varicella vaccine in healthy children: final report of a 2-year efficacy study and 7-year follow-up studies.
Kuter BJ; Weibel RE; Guess HA; Matthews H; Morton DH; Neff BJ; Provost PJ; Watson BA; Starr SE; Plotkin SA
Vaccine; 1991 Sep; 9(9):643-7. PubMed ID: 1659052
[TBL] [Abstract][Full Text] [Related]
2. Live attenuated varicella virus vaccine. Efficacy trial in healthy children.
Weibel RE; Neff BJ; Kuter BJ; Guess HA; Rothenberger CA; Fitzgerald AJ; Connor KA; McLean AA; Hilleman MR; Buynak EB
N Engl J Med; 1984 May; 310(22):1409-15. PubMed ID: 6325909
[TBL] [Abstract][Full Text] [Related]
3. Ten year follow-up of healthy children who received one or two injections of varicella vaccine.
Kuter B; Matthews H; Shinefield H; Black S; Dennehy P; Watson B; Reisinger K; Kim LL; Lupinacci L; Hartzel J; Chan I;
Pediatr Infect Dis J; 2004 Feb; 23(2):132-7. PubMed ID: 14872179
[TBL] [Abstract][Full Text] [Related]
4. Long-term protective immunity of recipients of the OKA strain of live varicella vaccine.
Asano Y; Nagai T; Miyata T; Yazaki T; Ito S; Yamanishi K; Takahashi M
Pediatrics; 1985 Apr; 75(4):667-71. PubMed ID: 2984636
[TBL] [Abstract][Full Text] [Related]
5. Over five-year follow-up of Oka/Merck varicella vaccine recipients in 465 infants and adolescents.
Clements DA; Armstrong CB; Ursano AM; Moggio MM; Walter EB; Wilfert CM
Pediatr Infect Dis J; 1995 Oct; 14(10):874-9. PubMed ID: 8584315
[TBL] [Abstract][Full Text] [Related]
6. Five-year follow-up study of recipients of live varicella vaccine using enhanced neutralization and fluorescent antibody membrane antigen assays.
Asano Y; Albrecht P; Vujcic LK; Quinnan GV; Kawakami K; Takahashi M
Pediatrics; 1983 Sep; 72(3):291-4. PubMed ID: 6310478
[TBL] [Abstract][Full Text] [Related]
7. Live attenuated varicella vaccine in healthy 12- to 24-month-old children.
Johnson CE; Shurin PA; Fattlar D; Rome LP; Kumar ML
Pediatrics; 1988 Apr; 81(4):512-8. PubMed ID: 2832819
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of one vs. two injections of Oka/Merck varicella vaccine in healthy children.
Ngai AL; Staehle BO; Kuter BJ; Cyanovich NM; Cho I; Matthews H; Keller P; Arvin AM; Watson B; White CJ
Pediatr Infect Dis J; 1996 Jan; 15(1):49-54. PubMed ID: 8684876
[TBL] [Abstract][Full Text] [Related]
9. Clinical survey of natural varicella compared with breakthrough varicella after immunization with live attenuated Oka/Merck varicella vaccine.
Bernstein HH; Rothstein EP; Watson BM; Reisinger KS; Blatter MM; Wellman CO; Chartrand SA; Cho I; Ngai A; White CJ
Pediatrics; 1993 Dec; 92(6):833-7. PubMed ID: 8233746
[TBL] [Abstract][Full Text] [Related]
10. Humoral immunity and clinical reinfections following varicella vaccine in healthy children.
Johnson C; Rome LP; Stancin T; Kumar ML
Pediatrics; 1989 Sep; 84(3):418-21. PubMed ID: 2549498
[TBL] [Abstract][Full Text] [Related]
11. Clinical application of a live varicella vaccine (Oka strain) in a hospital.
Naganuma Y; Osawa S; Takahashi R
Biken J; 1984 Sep; 27(2-3):59-61. PubMed ID: 6100059
[TBL] [Abstract][Full Text] [Related]
12. Persistence of cell-mediated and humoral immune responses in healthy children immunized with live attenuated varicella vaccine.
Watson B; Gupta R; Randall T; Starr S
J Infect Dis; 1994 Jan; 169(1):197-9. PubMed ID: 8277182
[TBL] [Abstract][Full Text] [Related]
13. Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response.
White CJ; Kuter BJ; Ngai A; Hildebrand CS; Isganitis KL; Patterson CM; Capra A; Miller WJ; Krah DL; Provost PJ
Pediatr Infect Dis J; 1992 Jan; 11(1):19-23. PubMed ID: 1312704
[TBL] [Abstract][Full Text] [Related]
14. Worldwide experience with the Oka-strain live varicella vaccine.
Andre FE
Postgrad Med J; 1985; 61 Suppl 4():113-20. PubMed ID: 3014468
[TBL] [Abstract][Full Text] [Related]
15. Experience and reason: twenty-year follow-up of protective immunity of the Oka strain live varicella vaccine.
Asano Y; Suga S; Yoshikawa T; Kobayashi I; Yazaki T; Shibata M; Tsuzuki K; Ito S
Pediatrics; 1994 Oct; 94(4 Pt 1):524-6. PubMed ID: 7936864
[No Abstract] [Full Text] [Related]
16. The safety profile of varicella vaccine: a 10-year review.
Galea SA; Sweet A; Beninger P; Steinberg SP; Larussa PS; Gershon AA; Sharrar RG
J Infect Dis; 2008 Mar; 197 Suppl 2():S165-9. PubMed ID: 18419392
[TBL] [Abstract][Full Text] [Related]
17. Attenuated varicella virus vaccine in children with renal transplants.
Zamora I; Simon JM; Da Silva ME; Piqueras AI
Pediatr Nephrol; 1994 Apr; 8(2):190-2. PubMed ID: 8018498
[TBL] [Abstract][Full Text] [Related]
18. A long-term prospective study of varicella vaccine in healthy children.
Johnson CE; Stancin T; Fattlar D; Rome LP; Kumar ML
Pediatrics; 1997 Nov; 100(5):761-6. PubMed ID: 9346974
[TBL] [Abstract][Full Text] [Related]
19. Association of steroid therapy with vaccine-associated rashes in children with acute lymphocytic leukaemia who received Oka/Merck varicella vaccine. NIAID Varicella Vaccine Collaborative Study Group.
Lydick E; Kuter BJ; Zajac BA; Guess HA
Vaccine; 1989 Dec; 7(6):549-53. PubMed ID: 2558454
[TBL] [Abstract][Full Text] [Related]
20. Clinical trial of the Oka strain of live attenuated varicella vaccine on healthy children.
Ozaki T; Matsui T; Ichikawa T; Asano Y; Yamanishi K; Takahashi M
Biken J; 1984 Sep; 27(2-3):39-42. PubMed ID: 6100056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
